Bioverativ Inc. Common Stock
BIVV
BIVV was delisted on the 8th of March, 2018.
459 hedge funds and large institutions have $5.76B invested in Bioverativ Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 127 increasing their positions, 175 reducing their positions, and 64 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
23% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 64
3% more funds holding
Funds holding: 446 → 459 (+13)
6% more call options, than puts
Call options by funds: $16.8M | Put options by funds: $15.8M
2% less capital invested
Capital invested by funds: $5.89B → $5.76B (-$135M)
27% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 175
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$177M |
| 2 |
BlackRock
New York
|
+$85.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$71.2M |
| 4 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$63.7M |
| 5 |
O
OppenheimerFunds
New York
|
+$46.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VH
ValueAct Holdings
San Francisco,
California
|
-$72.5M |
| 2 |
Goldman Sachs
New York
|
-$63.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$58.1M |
| 4 |
Jennison Associates
New York
|
-$56.4M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$46.9M |
BIVV Hedge Fund Activity: Q4 2017 in Review
459 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q4 2017, worth a combined $5.76B — down 2.3% from $5.89B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new BIVV positions and 64 closed out — a net gain of 15 holders — while 127 added to existing stakes and 175 trimmed.
The largest buyer was EdgePoint Investment Group, opening a new position worth an estimated $177M. The largest seller was ValueAct Holdings, exiting entirely with an estimated $72.5M sold.
- 459 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q4 2017, up from 446 in Q3 2017.
- Funds reported $5.76B of Bioverativ Inc. Common Stock stock for Q4 2017, down 2.3% quarter-over-quarter.
- 79 funds opened new Bioverativ Inc. Common Stock positions in Q4 2017 and 64 closed out, a net change of +15 holders.
- The largest Bioverativ Inc. Common Stock buyer in Q4 2017 was EdgePoint Investment Group, an estimated $177M added.
- The largest Bioverativ Inc. Common Stock seller in Q4 2017 was ValueAct Holdings, an estimated $72.5M sold.
Based on aggregated 13F filings for Q4 2017.